Keith W. Marshall - 02 Jun 2023 Form 4 Insider Report for Prometheus Biosciences, Inc.

Role
Chief Financial Officer
Signature
/s/ Timothy K. Andrews, attorney-in-fact for Keith W. Marshall
Issuer symbol
N/A
Transactions as of
02 Jun 2023
Net transactions value
+$242,302
Form type
4
Filing time
02 Jun 2023, 19:03:59 UTC
Previous filing
07 Apr 2023
Next filing
16 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXDX Common Stock Options Exercise $242,302 +78,162 +797% $3.10* 87,973 02 Jun 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXDX Stock Options (Right to Buy) Options Exercise $0 -78,162 -60% $0.000000 52,838 02 Jun 2023 Common Stock 78,162 $3.10 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction represents an exercise and hold of stock options by the Reporting Person for tax planning purposes.
F2 25% of the shares subject to the option vested and became exercisable on August 3, 2021, and 1/48th of the shares subject to the option vesting monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date.